It has a T-cell-dependent bispecific monoclonal antibody with two antigen recognition sites, one for HER2 and another one for the CD3 complex, which leads to the cross linking of HER2-expressing tumor cells and cytotoxic T lymphocytes. The gene discussed is ERBB2; the disease is neoplasm.